Compare Prudential PLC (PUK) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Repligen Corporation Common Stock — how do they compare? Prudential PLC trades at $23.79 (market cap $29.25B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Prudential PLC is far larger — about 2.6× Repligen Corporation Common Stock's market cap, and Prudential PLC pays a 2.33% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and Repligen Corporation Common Stock for 0 Days on average.
| PUK | RGEN | |
|---|---|---|
Market Cap | $29.25B | $11.31B |
Volume | 1,214,779 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $33.61 | $194.57 |
52-Week Low | $23.54 | $102.87 |
Typical Hold Time | 119 Days | 0 Days |
Enterprise Value | $28.79B | $11.20B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential (PUK) trades at $23.83, down 0.17% with a bearish technical signal. The company shows strong fundamentals with 2025 revenue of $27.39B and net income of $3.98B, supported by a 14.52% profit margin and attractive valuation ratios including a P/E of 8.38. Recent strategic moves include exiting emerging markets and focusing on core operations, with analyst consensus leaning positive despite mixed quarterly earnings performance.
The outlook remains cautiously optimistic given solid profitability and strategic repositioning, though risks include execution of the $3B capital rotation plan and market volatility. With 50% of analysts rating it Buy and technical indicators showing oversold conditions, the stock presents value potential for patient investors despite near-term bearish momentum.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
